This article was accepted into the corpus but its outbound wikilinks were never NER-processed — typical at the deepest BFS hop or when the run's entity cap was reached. No expansion funnel to show.
| FGFR1 | |
|---|---|
| Name | Fibroblast growth factor receptor 1 |
| Organism | Homo sapiens |
| Length | ~822 aa (isoforms vary) |
| Location | Chromosome 8 |
FGFR1 FGFR1 is a receptor tyrosine kinase involved in cell proliferation, differentiation, and survival, first characterized in studies by researchers at institutions such as Cold Spring Harbor Laboratory, Harvard University, and Massachusetts Institute of Technology. Mutations and translocations involving FGFR1 have been linked to developmental disorders and malignancies investigated at centers including Mayo Clinic, Johns Hopkins Hospital, and Memorial Sloan Kettering Cancer Center. Research on FGFR1 intersects work on Fibroblast growth factor, Receptor tyrosine kinases, Oncogenes, Signal transduction, and therapeutics developed by companies such as Novartis, Pfizer, and Roche.
The extracellular portion of FGFR1 contains three immunoglobulin-like domains akin to domains characterized in proteins studied at Max Planck Society and European Molecular Biology Laboratory, and a single-pass transmembrane helix comparable to membrane proteins resolved at RCSB PDB. The intracellular tyrosine kinase domain shares homology with kinases examined by labs at University of Cambridge, Stanford University, and University of Oxford. Alternative splicing produces isoforms with differing ligand specificities similar to splice variants investigated in work from Karolinska Institute and Yale University, and glycosylation patterns reflect findings reported by Scripps Research. Ligand binding prompts dimerization and autophosphorylation, a mechanism studied alongside receptors such as Epidermal growth factor receptor and Platelet-derived growth factor receptor at institutions like Imperial College London and University of California, San Francisco.
The FGFR1 gene maps to chromosome 8, a locus characterized in genomic projects led by Human Genome Project, 1000 Genomes Project, and researchers at Broad Institute. Germline mutations have been reported in cohorts from National Institutes of Health and Children's Hospital of Philadelphia, while somatic amplifications and fusions have been cataloged in datasets from The Cancer Genome Atlas and European Genome-phenome Archive. Tissue-specific expression profiles, profiled by consortia such as GTEx, demonstrate high expression in mesenchymal lineages and developing neural tissues, findings corroborated by single-cell atlases produced by teams at Wellcome Sanger Institute and Allen Institute for Brain Science.
FGFR1 activates canonical cascades including the RAS–MAPK pathway, PI3K–AKT axis, and PLCγ signaling, pathways elucidated in seminal studies from Cold Spring Harbor Laboratory and Weizmann Institute of Science. Cross-talk with receptor systems studied at Memorial Sloan Kettering Cancer Center and MD Anderson Cancer Center modulates outcomes in cell fate decisions; adaptor proteins such as FRS2 and GRB2 mediate links to downstream effectors, a mechanism explored in research from University of Michigan and University College London. Negative regulation through phosphatases and endocytic trafficking parallels regulatory themes reviewed by investigators at Duke University and University of Pennsylvania.
FGFR1 contributes to embryonic development processes mapped in model organisms at Max Planck Institute for Developmental Biology, European Molecular Biology Laboratory, and Fred Hutchinson Cancer Center. It is essential for mesodermal patterning, neural crest migration, and limb bud outgrowth, with phenotypes comparable to classical studies from Howard Hughes Medical Institute investigators and developmental programs described in textbooks used at Columbia University and University of Chicago. In adult physiology, FGFR1 signaling participates in angiogenesis, wound healing, and metabolic regulation, fields advanced by work at Brigham and Women's Hospital and University of Toronto.
Germline loss-of-function mutations manifest in syndromes studied at Boston Children's Hospital and Great Ormond Street Hospital, producing features in skeletal dysplasia cohorts similar to reports from University of California, Los Angeles and Ohio State University. Somatic FGFR1 alterations, including amplifications and translocations (e.g., fusions characterized in studies at Dana-Farber Cancer Institute), drive subsets of cancers such as glioblastoma, breast cancer, and lung squamous cell carcinoma cataloged in databases maintained by National Cancer Institute and Memorial Sloan Kettering Cancer Center. FGFR1 has also been implicated in psychiatric research programs at Yale University and University of Pittsburgh where links to neurodevelopmental phenotypes were explored.
Diagnostic assays detecting FGFR1 alterations utilize platforms from Illumina, Agilent Technologies, and Roche Diagnostics, and are implemented in clinical laboratories accredited by College of American Pathologists and regulated under frameworks from US Food and Drug Administration. Targeted therapies include small-molecule inhibitors and monoclonal antibodies developed by AstraZeneca, Bristol Myers Squibb, and Eli Lilly and Company; clinical trials run through networks like European Organisation for Research and Treatment of Cancer and National Cancer Institute assess efficacy in FGFR1-driven tumors. Resistance mechanisms reported by investigators at Vanderbilt University and University of Washington guide combination strategies incorporating agents used in protocols from Johns Hopkins University and Stanford University Medical Center.
Animal and cellular models used to study FGFR1 include mouse knockouts created at The Jackson Laboratory and zebrafish morphants developed by groups at University of Oregon and University of Edinburgh, as well as organoid systems pioneered by teams at Hubrecht Institute and University College London. Structural studies using cryo-EM and X-ray crystallography have been performed at facilities like European Synchrotron Radiation Facility and Diamond Light Source, while high-throughput screening campaigns have been conducted at Genentech and Illumina Cambridge Ltd.. Ongoing international collaborations involve consortia such as Human Cell Atlas and translational networks coordinated by European Molecular Biology Laboratory.
Category:Receptor tyrosine kinases Category:Human proteins